Trends and Perspectives of Ruthenium Anticancer Compounds (Non-PDT)
- Author(s)
- Michael Jakupec, Wolfgang Kandioller, Beatrix Schönhacker-Alte, Robert Trondl, Walter Berger, Bernhard Keppler
- Abstract
Ruthenium is known as one of the most attractive metals for development of anticancer drugs. Three ruthenium(III) complexes were so far evaluated in clinical studies in cancer patients, with overall encouraging results. Specifically, NAMI-A, (im)[trans-RuIIICl4 (dmso)(Him)] (Him = imidazole), has been developed as an antimetastatic agent, but might require efficient tumor delivery strategies to raise its therapeutic index. KP1019, (ind)[trans-RuIIICl4 (Hind)2] (Hind = indazole), was originally developed with a focus on colorectal cancer, but clinical phase I data suggest broader activity. However, insufficient solubility for administration of a maximum tolerated dose prompted researchers to halt its development in favor of NKP-1339, Na[trans-RuIIICl4 (Hind)2]. For the latter, remarkable effects in carcinoid neuroendocrine tumors (and other solid tumors) were reported from a phase I trial. Based on quite different approaches, organometallic ruthenium(II) complexes are currently being studied preclinically, and keystone developments of these novel metallodrugs are discussed.
- Organisation(s)
- Department of Inorganic Chemistry
- External organisation(s)
- Research Cluster Translational Cancer Therapy Research, Medizinische Universität Wien
- Pages
- 271-291
- No. of pages
- 21
- DOI
- https://doi.org/10.1002/9783527695225.ch14
- Publication date
- 11-2017
- Peer reviewed
- Yes
- Austrian Fields of Science 2012
- 104003 Inorganic chemistry, 301904 Cancer research
- Keywords
- ASJC Scopus subject areas
- General Chemistry
- Sustainable Development Goals
- SDG 3 - Good Health and Well-being
- Portal url
- https://ucrisportal.univie.ac.at/en/publications/b3c516e2-a7d5-499d-873e-16a65018acb8